George Rho
Research analyst, long/short equity, special situations, arbitrage

Acadia Pharmaceuticals: Much More Room To Run

The common shares of this small company appreciated an astounding 1,064% in the past 12 months. Following such a showing, it would be easy to dismiss the equity as "overbought," expensive, and unworthy of any serious consideration as a potential addition to one's portfolio. It's not that simple when it comes to the biopharmaceutical sector, however, as the record shows that eye-popping historical percentage gains don't necessarily preclude additional compelling returns in the future. This assessment certainly applies to MannKind (NASDAQ:MNKD) and Keryx Biopharm. (NASDAQ:KERX), both of which we've recommended in recent months. The company whose shares performed so incredibly well is ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and we think the biotech's research and development...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details